Charcoal - Kureha

Drug Profile

Charcoal - Kureha

Alternative Names: AST-120; Kremezin; Kremezin Fine Granules; MP-146; Zysa

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kureha Corporation
  • Developer Daiichi Sankyo Pharmaceutical (Shanghai); Kureha Corporation; Mitsubishi Tanabe Pharma Corporation; Ocera Therapeutics
  • Class Absorbents
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal failure
  • Discontinued Crohn's disease; Gastro-oesophageal reflux; Hepatic encephalopathy; Irritable bowel syndrome; Pouchitis

Most Recent Events

  • 16 Jan 2018 Launched for Renal failure in Japan (PO, Tablet)
  • 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt plc
  • 15 Aug 2017 Registered for Renal failure in Japan (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top